spacer
home > ebr > spring 2019 > the authenticity of synthetics
PUBLICATIONS
European Biopharmaceutical Review

The Authenticity of Synthetics

Synthetic biology is a newly coined term for the design and construction of novel artificial biological pathways, organisms, or devices or the redesign of existing natural biological systems (1). Generally, it assumes an element of scale and the application of engineering-like techniques to solve biological problems through a rational process of ‘biodesign’. The field of synthetic biology brings together skills from biology and chemistry to computing, bioinformatics, and engineering. This emerging field is greatly anticipated to deliver significant and broad impact across a range of potential applications, among them the drug discovery and development field. However, to achieve its full potential, synthetic biology will require the continued development and convergence of its underlying skills and disciplines to enable the rational and predictable design of biological systems. As DNA is a fundamental building block of synthetic biology, the key to its success will be the ability to synthesise DNA at scale and with high accuracy.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Tim Brears is CEO at Evonetix, where he leads the company in developing a benchtop DNA writer to transition DNA synthesis from a service industry to one where scientists can make genes at will. He holds a PhD from the University of Cambridge, UK, and has an MBA from Duke University’s Fuqua School of Business, US.
spacer
Dr Tim Brears
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Nemeras preservative-free multidose eye dropper Novelia® approved for Santens Cosopt® for Glaucoma treatments in 29 European countries

Nemera is pleased to announce that its multidose eye dropper Novelia® has been approved for the preservative-free formulation Cosopt iMulti® (20mg/ml dorzolamide + 5mg/ml timolol eye drops, solution).
More info >>

White Papers

Customising the Cold Chain

World Courier

Of all the statistics emerging around the global pharmaceutical industry this year, two big numbers capture the attention of both manufacturers and their logistics partners: $248 billion, the amount the “BRIC” nations (Brazil, Russia, India and China) are poised to account for in pharmaceutical sales for by 2016; and $8 billion, the amount global pharma will spend on cold chain logistics in 2014. Why are these two numbers so noteworthy? They demonstrate that as R&D goes, so goes logistics. As products evolve to meet demands for more targeted therapies, demand for more targeted logistics solutions grows as well. And that means a need for customization for everything from clinical trial samples to finished product.
More info >>

 
Industry Events

SMi Presents the 11th Adaptive Designs in Clinical Trials Conference 2019

1-2 April 2019, Holiday Inn Kensington Forum, London

SMi Group are proud to announce the 11th annual Adaptive Designs in Clinical Trials conference and exhibition will return to London from the 1st – 2nd April 2019. With the growing popularity in use and acceptance of adaptive designs in clinical trials - demonstrated most recently with the new FDA draft guidance on adaptive designs – there is a pressing need for a forum which explores this increasingly normalized medical methodology.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement